Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC (ZFGN)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
3.51(c) 3.57(c) 4.03(c) 4.14(c) 3.94(c) Last
158 839 193 494 520 189 255 593 155 383 Volume
+3.24% +1.71% +12.89% +2.73% -4.83% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -59,4 M
Net income 2017 -60,5 M
Finance 2017 75,6 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -70,0 M
Net income 2018 -71,0 M
Finance 2018 119 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 114 M
More Financials
Company
Zafgen, Inc. is a biopharmaceutical company, which is engaged in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways.Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi... 
More about the company
Latest news on ZAFGEN INC
10/16 ZAFGEN : Reports Inducement Grant under NASDAQ Listing Rule 5635
10/12 ZAFGEN, INC. (NASDAQ : ZFGN) Files An 8-K Departure of Directors or Certain Offi..
10/12 ZAFGEN, INC. : Change in Directors or Principal Officers, Other Events, Financia..
10/12 Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10/12 ZAFGEN : Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph..
10/10 Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, P..
09/21 ZAFGEN : to Present at the 2017 Ladenburg Thalmann Healthcare Conference
09/19 Zafgen to Present at the 2017 Ladenburg Thalmann Healthcare Conference
09/15 ZAFGEN : Initiates Phase 2 Clinical trial for ZGN 1061 in Patients with Type 2 D..
09/14 ZAFGEN : Presents New Preclinical Data on ZGN 1061 at the 53rd Annual Meeting of..
More news
Sector news : Bio Therapeutic Drugs
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/16Zafgen upgraded by ValuEngine to sell.  
10/13Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)  
10/12Zafgen downgraded by Zacks Investment Research to hold.  
10/12Top Gainers: $INFI +81%. $ARDX +52%. $CCCL +19%. $CCCR +18%. $ONCS +17%. $ISD..
5
10/12Healthcare - Top 5 Gainers / Losers as of 11:00 am  
More tweets
Qtime:136
News from SeekingAlpha
10/12 Midday Gainers / Losers
10/12 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
10/10 Zafgen appoints Jeffrey Hatfield as CEO; Thomas Hughes to continue as Preside..
09/27 Zafgen (ZFGN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Sli..
09/12 Zafgen launches mid-stage study of ZGN-1061 in type 2 diabetics; shares ahead..
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | ZFGN | US98885E1038 | 4-Traders
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 6,67 $
Spread / Average Target 61%
EPS Revisions
Managers
NameTitle
Jeffrey S. Hatfield Chief Executive Officer & Director
Thomas E. Hughes President, Chief Scientific Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO, Treasurer & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC30.19%114
GILEAD SCIENCES13.35%106 002
REGENERON PHARMACEUTICALS20.67%47 464
VERTEX PHARMACEUTICALS107.56%38 551
ACTELION23.24%29 919
GENMAB22.08%13 910